Figure 5. HK2 is required for antitumor immunity.

a,b, Tumor growth (a) and survival (b) curves of Hk2^tKO or wildtype (WT) control mice injected s.c. with 10⁵ B16F10 melanoma cells for the indicated time periods. c,d, Flow cytometric analysis of the frequency and absolute number of CD4⁺ and CD8⁺ T cells (c) and IFN-γ-producing CD8⁺ effector T cells (d) in day 20 tumor of the B16F10-implanted Hk2^tKO and wildtype control mice (c,WT: n=9; Hk2^tKO: n=8; d, n=5 per genotype). e, Tumor growth curve of MC38 tumor-bearing wildtype, NIK^iTg (iTg), and NIK^iTgHk2^iKO (iTg-iKO) mice. f,g, Flow cytometric analysis of the frequency and absolute cell number of IFN-γ-producing CD8⁺ T cells (f) and gated PD1⁺Tim3⁺ CD8⁺ T cells (g) in day-27 tumor of the MC38 tumor-bearing mice (f,g, WT: n=4, iTg: n=4, iTg-iKO: n=3) . Data are representative of two (e-g) or three (a-d) independent experiments. Flow cytometry data are presented as representative plots (left) and summary graphs (mean ± s.e.m.) based on multiple mice (right, each circle represents an individual mouse). P values were determined by two-way analysis of ANOVA with Bonferroni correction (a,e), two-tailed Student’s t test (c,d,f,g) or two sided log- rank test (b).